Dexamethasone intratympanic - Otonomy

Drug Profile

Dexamethasone intratympanic - Otonomy

Alternative Names: OTIVIDEX; OTO-104; Sustained release dexamethasone

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otonomy
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Meniere's disease; Sensorineural hearing loss

Most Recent Events

  • 08 Nov 2017 Positive efficacy and adverse events data from a phase III AVERTS-2 trial in in Meniere's disease released by Otonomy
  • 08 Nov 2017 Otonomy intends to review results of the AVERTS phase III trials of dexamethasone intratympanic for Meniere's disease with US FDA in the first quarter of 2018
  • 13 Sep 2017 Ontology terminates a phase III trial for Meniere's Disease due to negative efficacy results in USA, Germany, Belgium and United Kingdom (Intratympanic) (NCT02768662)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top